XOMA licenses anti-TGFb antibody programme to Novartis
2 October 2015 | By Victoria White
Elevated levels of TGFb may drive the progression of advanced metastatic cancer. As such, it has become an attractive target for cancer drug development...
List view / Grid view
News
Researchers disguise anti-cancer drugs as platelets
2 October 2015 | By Victoria White
The technique allows drugs to last longer in the body and attack both primary cancer tumours and the circulating tumour cells...
Genisphere raises $4m in funding to extend its 3DNA platform
2 October 2015 | By Victoria White
Genesphere's goal is to license the 3DNA platform to pharmaceutical partners and complete the preclinical work necessary to advance the its own lead drug candidates...
Scientists develop drug to prevent diabetic enteropathy
2 October 2015 | By Victoria White
Scientists have discovered a protein that 'soaks up' the overproduced hormone that leads to diabetic enteropathy...
1000 Genomes Project team create largest catalogue of genomic differences
2 October 2015 | By Victoria White
Understanding how genomic variants contribute to disease may help clinicians develop improved diagnostics and treatments, in addition to new methods of prevention...
Receptor identified as potential target for treatment of autism
1 October 2015 | By Victoria White
Scientists have uncovered a relationship between a chemical that helps transmit signals in the brain and genetic mutations present in a subset of individuals with autism...
Drug discovery initiative TaNeDS opens for applications
1 October 2015 | By Victoria White
The TaNeDS programme provides close partnership between successful applicants and scientists in Daiichi Sankyo to tackle unmet medical needs...
Cancer stopped in its tracks by reprogrammed fibroblasts
1 October 2015 | By Victoria White
If further studies show this route can benefit patients, it could help crack one of the toughest challenges in cancer research – how to stop tumours spreading...
FDA grants orphan drug designation to BLU-554
30 September 2015 | By Victoria White
BLU-554, an exquisitely selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), is currently being evaluated in a Phase 1 clinical trial in patients with advanced hepatocellular carcinoma...
Aspen Park acquires rights to castration resistant prostate cancer drug
30 September 2015 | By Victoria White
APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer...
UbiVac and Janssen to develop vaccine to intercept oral cancer
30 September 2015 | By Victoria White
Development of an immunotherapy that induced broad anti-cancer immunity and inhibited oral leukoplakia from transforming into oral cancer would represent a paradigm shift for treating this disease...
CARsgen partners with Shanghai Cancer Institute to advance CAR-T therapies
30 September 2015 | By Victoria White
The partners will work together to identify and develop novel CAR-T candidates as well as next-generation CAR-T technologies...
Innovate UK awards Congenica £300,000
29 September 2015 | By Victoria White
Congenica’s platform Sapientia has been developed to analyse and interpret whole genome data. With this grant Congenica will be able to extend its capability to include other types of -omics data...
New company LA Cell to focus on cell-penetrating antibody therapies
29 September 2015 | By Victoria White
LA Cell has exclusively licensed technology that enables modified monoclonal antibodies to penetrate into cells and target "undruggable" disease-causing molecules...
Apitope raises €12 million in Series B funding
29 September 2015 | By Victoria White
The funds will enable Apitope to progress the clinical development of its innovative pipeline which includes therapies for Factor VIII intolerance in Haemophilia A patients...